|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
MondayAdeona Announces Completion of 50% Enrollment in Trimesta(TM) Multiple Sclerosis Clinical Trial
(Posted by Desinie Smith)
Adeona Pharmaceuticals, Inc. announced today that the clinical trial of it's investigational drug Trimesta (TM) ( estriol oral) being conducted by principal investigator Dr. Rhonda Voskuhl ( Director UCLA Dept. of Neurology) has enrolled over 75 patients. The total planned enrollment is 150 patients. The Trimesta (TM) study is a double-blind, placebo-controlled clinical trial. Sixteen sites in the United States are currently enrolling patients. Investigators at these clinical sites are administering either Trimesta (TM) along with glatimer acetate (Copaxone) , to women between the ages of 18 to 50 who have been recently diagnosed with relapsing-remitting multiple sclerosis. Read the rest of the article here on marketwatch.com. Labels: Clinical Trials |